

IMMUNOGEN INC

Reported by
RYLL THOMAS

FORM 3

(Initial Statement of Beneficial Ownership)

Filed 04/06/17 for the Period Ending 03/29/17

Address	830 WINTER ST WALTHAM, MA 02451
Telephone	(781)895-0600
CIK	0000855654
Symbol	IMGN
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	06/30

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol		
Ryll Thomas			3/29/2017		IMMUNOGEN INC [IMGN]		
(Last) (First) (Middle)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
C/O IMMUNOGEN, INC., 830 WINTER STREET			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) VP, Technical Operations /				
(Street)			5. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line)		
WALTHAM, MA 02451					<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip)							

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	106600 (5)	D	
Common Stock	1500	D	

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	8/17/2016 (1)	8/17/2025	Common Stock	60000	\$14.56	D	
Stock Option (right to buy)	6/1/2017 (2)	6/1/2026	Common Stock	4000	\$5.75	D	
Stock Option (right to buy)	7/18/2017 (3)	7/18/2026	Common Stock	40000	\$3.05	D	
Stock Option (right to buy)	9/30/2017 (4)	9/30/2026	Common Stock	38000	\$2.68	D	

Explanation of Responses:

- (1) 15,000 shares exercisable as of filing date, 15,000 shares exercisable commencing on August 17, 2017, 15,000 shares exercisable commencing on August 17, 2018 and 15,000 shares exercisable commencing on August 17, 2019.
- (2) Exercisable as to 1,334 shares commencing on June 1, 2017, 1,333 shares exercisable commencing on June 1, 2018, and 1,334 shares exercisable commencing on June 1, 2019.
- (3) Exercisable as to 13,334 shares commencing on July 18, 2017, 13,333 shares commencing on July 18, 2018, and 13,333 shares commencing on July 18, 2019.
- (4) Exercisable as to 12,667 shares commencing on September 30, 2017, 12,667 shares commencing on September 30, 2018, and 12,666 shares commencing on September 30, 2019.

(5) These shares are restricted stock which vest annually in three equal installments commencing on February 21, 2018.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Ryll Thomas C/O IMMUNOGEN, INC. 830 WINTER STREET WALTHAM, MA 02451			VP, Technical Operations	

Signatures

/s/ Craig Barrows, attorney in fact

4/6/2017

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.